Amgen’s Repatha Reduces Heart Attack Risk by 36%

Researchers have unveiled significant findings regarding Amgen’s Repatha, a cholesterol-lowering injection that has been available for nearly ten years. The latest study indicates that Repatha can substantially decrease the risk of heart attacks and strokes in patients who are at high risk but have not yet experienced these serious cardiovascular events.

Study Outcomes on Repatha’s Effectiveness

A recent study published in the New England Journal of Medicine highlights the drug’s impressive efficacy. The research, presented at the American Heart Association’s scientific sessions, reveals that Repatha reduced coronary heart disease deaths, heart attacks, and strokes by 25% overall. Notably, it lowered the risk of first heart attacks by 36% among individuals with high cholesterol who had no prior history of these events.

Clinical Implications

• Participants had high cholesterol levels and were already on statins or other cholesterol-lowering medications.
• Repatha not only cut down major cardiovascular problems but also helped in preventing the necessity for invasive procedures like stents or bypass surgeries.

This study, known as VESALIUS-CV, illustrated that Repatha’s benefits surpass those of traditional statin therapy, which has long been known as a leading class of cholesterol-lowering agents.

Conclusion

As cardiovascular disease continues to be a leading cause of death globally, findings from this study provide hope for high-risk patients. Amgen’s Repatha offers a promising option that could significantly lower the risk of heart attacks and strokes.